Mr. Iain Weir-Jones reports

APPOINTMENT OF NEW DIRECTOR

Shumsheer Sidhu, BSc, has accepted the invitation of Med BioGene Inc.'s directors to join the board. Ms. Sidhu is a graduate of the University of British Columbia and is both a certified management accountant (CMA) and chartered professional accountant (CPA). Since graduation, she has worked in the health care sector in a financial management capacity. She is currently the finance manager at NeuroDevNet, the first trans-Canada initiative dedicated to studying children's brain development.

Ms. Sidhu has been a shareholder of the company since 2013 and has a substantial interest in the long-term growth of this company.

This appointment is in accordance with the previously stated policy of the company to diversify the management and board by involving representatives of the shareholders at the board level, and to become more responsive to the concerns of the shareholders at large. Ms. Sidhu shares this objective and will become a member of the company's audit committee under the chairmanship of David Diebolt, CA.

In accordance with the policy outlined before the last annual general meeting, Ms. Sidhu has agreed to forgo director fees until the company's GeneFX Lung has been commercialized and positive cash flow has been achieved. The company hopes to announce commercialization in the fourth quarter of 2015 and is working with its development partner Helomics to make this a reality.

We seek Safe Harbor.